Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
FDA aligned on single-arm Phase 3 study to support potential accelerated and full approval On track to dose first patient in Phase 3 trial in second half of 2025 LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) ...
GEN1h
Optimizing AAV Gene Delivery: Hitting the Target Safely and Effectively
Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.
GEN1h
AI-Enabled Gene Editing Produces Fewer Off-Target Outcomes
By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.
FY2026 EPS Estimates for REGENXBIO Raised by Leerink Partnrs
Investment analysts at Leerink Partnrs lifted their FY2026 EPS estimates for REGENXBIO in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst M. Foroohar now expects that the ...